| [1] |
Xu Z, Wang L, Dai S, et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States[J]. JAMA Netw Open, 2021, 4(9):e2124750.
|
| [2] |
Lou X, Qin Y, Xu X, et al. Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(5):188782.
|
| [3] |
de Ponthaud C, Menegaux F, Gaujoux S. Updated principles of surgical management of pancreatic neuroendocrine tumours (pNETs):what every surgeon needs to know[J]. Cancers, 2021, 13(23):5969.
|
| [4] |
中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版)[J]. 中国癌症杂志, 2022, 32:545-580.
|
| [5] |
Maggino L, Schmidt A, Käding A, et al. Reappraisal of a 2 cm cut-off size for the management of cystic pancreatic neuroendocrine neoplasms: a multicenter international study[J]. Pancreatology, 2019, 19:S67-68.
|
| [6] |
Krogh S, Grønbæk H, Knudsen AR, et al. Predicting progression, recurrence, and survival in pancreatic neuroendocrine tumors: a single center analysis of 174 patients[J]. Front Endocrinol, 2022, 13: 925632.
|
| [7] |
Ricci C, Partelli S, Landoni L, et al. Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours[J]. Br J Surg, 2022, 109(8):733-738.
|
| [8] |
Giuliani T, De Pastena M, Paiella S, et al. Pancreatic enucleation patients share the same quality of life as the general population at long-term follow-up: a propensity score-matched analysis[J]. Ann Surg, 2023, 277(3):e609-616.
|
| [9] |
Bolm L, Nebbia M, Wei AC, et al. Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 cm in a large multicenter cohort[J]. Ann Surg, 2022, 276(3):522-531.
|
| [10] |
Titan AL, Norton JA, Fisher AT, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11):e2024318.
|
| [11] |
Heidsma CM, Tsilimigras DI, Rocha F, et al. Identifying risk factors and patterns for early recurrence of pancreatic neuroendocrine tumors: a multi-institutional study[J]. Cancers, 2021, 13(9):2242.
|
| [12] |
Hsu D, Le S, Chang A, et al. Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?[J]. J Clin Oncol, 2021, 39(15 Suppl):4108.
|
| [13] |
Tanaka M, Heckler M, Mihaljevic AL, et al. Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors[J]. Ann Surg Oncol, 2021, 28(3):1614-1624.
|
| [14] |
Altimari M, Abad J, Chawla A. The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors[J]. HPB, 2021, 23(10):1533-1540.
|
| [15] |
Holmager P, Langer SW, Kjaer A, et al. Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high grade mixed neuroendocrine-non-neuroendocrine neoplasms[J]. Curr Treat Options Oncol, 2022, 23(6):806-817.
|
| [16] |
Asano D, Kudo A, Akahoshi K, et al. Curative surgery and Ki-67 value rather than tumor differentiation predict the survival of patients with high-grade neuroendocrine neoplasms[J]. Ann Surg, 2022, 276(2):e108-113.
|
| [17] |
Raoul JL, Heymann MF, Dumont F, et al. Case report: grade 2 metastatic pancreatic neuroendocrine tumor with progression of one metastasis after pregnancy to grade 3 large-cell neuroendocrine carcinoma: one case cured by resection with genomic characterization of the two components[J]. Front Oncol, 2021, 11: 646992.
|
| [18] |
Pelosi G, Bianchi F, Dama E, et al. A subset of large cell neuroendocrine carcinomas in the gastroenteropancreatic tract may evolve from pre-existing well-differentiated neuroendocrine tumors[J]. Endocr Pathol, 2021, 32(3):396-407.
|
| [19] |
Mou Y, Wang ZY, Tan CL, et al. The role of primary tumor resection in patients with pancreatic neuroendocrine tumors with liver metastases[J]. Front Oncol, 2022, 12: 838103.
|
| [20] |
Yang Z, Liang J, Leng K, et al. Survival benefit of surgical resection for pancreatic neuroendocrine tumors with oligometastatic liver metastasis: a retrospective and propensity score-matching analysis[J]. Front Oncol, 2022, 12:903560.
|
| [21] |
You T, Tang H, Xu X, et al. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: a 20-year single-center retrospective analysis[J]. J Neuroendocrinol, 2022, 34(12):e13211.
|
| [22] |
Kaemmerer D, Twrznik M, Kulkarni HR, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms[J]. Ann Surg, 2021, 274(1):e45-53.
|
| [23] |
Eshmuminov D, Studer DJ, Lopez Lopez V, et al. Controversy over liver transplantation or resection for neuroendocrine liver metastasis: tumor biology cuts the deal[J]. Ann Surg, 2023, 277(5):e1063-1071.
|
| [24] |
Hibi T, Rela M, Eason JD, et al. Liver transplantation for colorectal and neuroendocrine liver metastases and hepatoblastoma. working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6):1131-1135.
|
| [25] |
Maspero M, Rossi RE, Sposito C, et al. Long-term outcomes of resection versus transplantation for neuroendocrine liver metastases meeting the Milan criteria[J]. Am J Transplant, 2022, 22(11):2598-2607.
|
| [26] |
Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial[J]. JAMA Oncol, 2022, 8(10):1447-1455.
|
| [27] |
Das S, Phillips S, Lee CL, et al. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - a systematic review and meta-analysis[J]. Eur J Cancer, 2023, 182:43-52.
|
| [28] |
Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)[J].J Clin Oncol, 2023, 41(7):1359-1369.
|
| [29] |
Li Y, Fan Z, Zhang F, et al. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12:981575.
|
| [30] |
吴峻立, 苗毅. 胰腺神经内分泌肿瘤肝转移术前评估和外科治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(1):6-10.
|
| [31] |
Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2022, 5(2):e220290.
|
| [32] |
Chiti G, Grazzini G, Flammia F, et al. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a radiomic model to predict tumor grade[J]. Radiol Med, 2022, 127(9):928-938.
|
| [33] |
Javed AA, Pulvirenti A, Razi S, et al. Grading pancreatic neuroendocrine tumors via endoscopic ultrasound-guided fine needle aspiration: a multi-institutional study[J]. Ann Surg, 2023, 277(6):e1284-1290.
|
| [34] |
Liu C, Bian Y, Meng Y, et al. Preoperative prediction of G1 and G2/3 grades in patients with nonfunctional pancreatic neuroendocrine tumors using multimodality imaging[J]. Acad Radiol, 2022, 29(4):e49-60.
|
| [35] |
Wang M, Ding D, Qin T, et al. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification[J]. Cancer Lett, 2021, 518:207-213.
|
| [36] |
Wang WQ, Zhang WH, Gao HL, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4):395-405.
|
| [37] |
Pulvirenti A, Javed AA, Landoni L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6):1051-1057.
|
| [38] |
Hua J, Shi S, Xu J, et al. Expression patterns and prognostic value of DNA damage repair proteins in resected pancreatic neuroendocrine neoplasms[J]. Ann Surg, 2022, 275(2):e443-452.
|
| [39] |
王先泽, 吴文铭. 胰腺神经内分泌肿瘤外科治疗理念的四种转变[J]. 中国癌症杂志, 2022, 32(9):765-771.
|